A Multicenter, Single-Blind, Within-Subject, Placebo-Controlled Proof of Concept Study to Assess the Effect of Single Oral Doses of BGG492 on the Photoparoxysmal EEG Response in Patients With Photosensitive Epilepsy
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Selurampanel (Primary)
- Indications Reflex epilepsy
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 04 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 07 May 2009 New trial record.